Our Science

    Our Science

    Pioneering the unseen.

    Our comprehensive investigation into the pathophysiology of androgenic alopecia has revealed a range of complex mechanisms contributing to hair loss and thinning.
    In response, we focused on the development of targeted molecules designed to address each of these mechanisms individually.
    Each molecule underwent extensive preclinical and clinical testing to confirm
    both efficacy and safety, with the results published in 2024.

    A human clinical trial, conducted with rigorous controls, demonstrated a statistically significant increase in hair count when compared to the placebo group.
    TrinogeniX™, a proprietary blend of three patented ingredients, offers a scientifically backed solution that delivers tangible and lasting results.

    Development History

    2022~2024

    • Human clinical trial

    2021~2022

    • in-vivo / ex-vivo efficacy evaluation

    2021

    • Target molecule development
    • Disease MoA (Mechanism of Action) identification

    TrinogeniX™ in detail and its clinical benefits

    TrinogeniX™ in detail and its clinical benefits

    Renovodole : Fill
    Renovodole, an inhibitor of prostaglandin degrading enzyme (15-prostaglandin dehydrogenase), stimulates hair regeneration by activating hair follicle stem cells with increasing prostaglandin E2 (PGE2) concentration.
    Publications

    Renovozol, a GPR44 antagonist, stimulates hair growth by elongating anagen period with blocking the action of prostaglandin D2 (PGD2), which is known to inhibit hair growth.

    Publications

    Renovoridine, a glycogen phosphorylase enzyme inhibitor, stimulates hair growth by inhibiting catagen entry with modulating energy metabolism and blocking reactive oxygen species (ROS).

    Publications